In a BM xenograft model, tucatinib penetrated intracranial tumor tissues, inhibited tumor growth, and improved survival, positioning tucatinib as a potentially optimal TKI partner for HER2-targeted therapy in HER2 + BCBM [61]. The gene discussed is ERBB2; the disease is neoplasm.